Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Interest Expenses (2024 - 2025)

Indivior Pharmaceuticals (INDV) has 2 years of Interest Expenses data on record, last reported at $6.0 million in Q4 2025.

  • For Q4 2025, Interest Expenses fell 53.85% year-over-year to $6.0 million; the TTM value through Dec 2025 reached $45.0 million, up 9.76%, while the annual FY2025 figure was $45.0 million, 9.76% up from the prior year.
  • Interest Expenses reached $6.0 million in Q4 2025 per INDV's latest filing, down from $12.0 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $15.0 million in Q2 2025 and bottomed at $6.0 million in Q4 2025.